Cellagentech/BMS-232632 (Atazanavir) | HIV-1 protease inhibitor/C2232-5/5 mg (powder)
Product Description
Atazanavir (BMS-232632) is an orally available, azapeptide human immunodeficiency virus type 1 (HIV-1) protease inhibitor with EC50 of 2.6-5.3 nM, and EC90 of 9-15 nM. [1] Atazanavir has been shown to be effective in HIV-1 strains resistant to other antivirals such as nelfinavir, saquinavir, and amprenavir. Additionally, indinavir- and ritonavir-resistant strains are more six- to nine-fold more sensitive to atazanavir.Atazanavirs is highly selective for HIV-1 protease and only exhibits cytotoxic effects in 6500- to 23000-fold higher concentrations than is required for anti-HIV activity. Atazanavir has been shown to be additive or synergistic with a number of different antiviral therapies without antagonistic anti-HIV activity or cytotoxicity. [2, 3]
Technical information:
| Chemical Formula: | C38H52N6O7 | |
| CAS #: | 198904-31-3, 229975-97-7 | |
| Molecular Weight: | 704.86 | |
| Purity: | > 99% | |
| Appearance: | White | |
| Chemical Name: | 2,5,6,10,13-Pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-, 1,14-dimethyl ester, (3S,8S,9S,12S)- | |
| Solubility: | Up to 100 mM in DMSO | |
| Synonyms: | BMS-232632, BMS 232632, BMS232632, Atazanavir, Reyataz, CGP-73547 |
Shipping Condition: The product is shipped in a glass vial at ambient temperature. Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.
Reference:
| 1. | Gong et al., In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrobial Agents Chemother. 2000, 44(9), 2319-2326. Pubmed ID: 10952574 |
| 2. | Robinson et al., BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrobial Agents Chemother. 2000, 44(8), 2093-2099. Pubmed ID: 10898681 |
| 3. | Colonno et al., Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrobial Agents Chemother. 2003, 47(4), 1324-1333. Pubmed ID: 12654666 |
本文链接： https://www.ebiomall.cn/b83-cellagentech/info-1548391648.html
